Dominguez-Gonzalez, Cristina
Badosa, Carmen
Madruga-Garrido, Marcos
Martí, Itxaso
Paradas, Carmen
Ortez, Carlos
Diaz-Manera, Jordi
Berardo, Andres
Alonso-Pérez, Jorge
Trifunov, Selena
Cuadras, Daniel
Kalko, Susana G.
Blázquez-Bermejo, Cora
Cámara, Yolanda
Martí, Ramon
Mavillard, Fabiola
Martin, Miguel A.
Montoya, Julio
Ruiz-Pesini, Eduardo
Villarroya, Joan
Montero, Raquel
Villarroya, Francesc
Artuch, Rafael
Hirano, Michio
Nascimento, Andrés
Jimenez-Mallebrera, Cecilia
Article History
Received: 22 January 2020
Accepted: 13 May 2020
First Online: 22 June 2020
Competing interests
: MH, RM, Columbia University Medical Center (CUMC), and the Vall d’Hebron Research Institute (VHIR) have filed patent applications for deoxynucleoside and deoxynucleotide therapies for human mitochondrial DNA depletion and deletions syndrome including TK2 deficiency. RM, YC, CB, VHIR, and The Biomedical Network Research Centre on Rare Diseases (CIBERER) have filed patent applications covering potential use of deoxynucleoside treatment for POLG deficiency and other mtDNA replication defects in humans. CUMC, VHIR, and CIBERER have licensed pending patent applications related to these technologies to Modis Therapeutics, Inc. CUMC, VHIR, and CIBERER may be eligible to receive payments related to the development and commercialization of the technologies. Any potential licensing fees earned will be paid to CUMC, VHIR, and CIBERER and are shared with all inventors mentioned above through VHIR and CIBERER policies on distribution and objectivity in research. MH and RM serve as paid consultants to Modis Therapeutics, Inc. and RM has equity in this company. RM, YC, CB, VHIR, and The Biomedical Network Research Centre on Rare Diseases (CIBERER) have filed patent applications covering the potential use of deoxynucleoside treatment as a way to increase mtDNA copy number.